Skip to content

Ironwood Pharmaceuticals IRWD Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$40.77M+209%$0-100%$40.08M+999%$23.6M+2,844%-$37.39M-798%
$443K-7.5%$460K-5.2%$475K-6.3%$467K-7.7%$479K-6.6%
$3.65M-31.0%$3.82M-16.3%$3.61M-56.6%$4.52M-47.2%$5.29M-36.9%
$19.2M+2,765%$0-100%$27.77M+262%$14.11M+6.4%$670K-88.9%
$59.1M+240%-$73.62M$34.19M$46.4M+434%-$42.12M+26.2%
-$4.89M-151%$0+100%$10.69M-$13.84M-592%$9.66M+177%
-$6M-1,573%-$1.09M+52.1%$248K$64K$407K-84.4%
-$219K-217%$0+100%$249K-94.4%$3.67M-36.5%$187K-84.0%
$444K+8.6%$435K+8.2%$426K+8.4%$418K+8.6%$409K+8.2%
-$621K-8.6%-$612K-8.9%-$603K-8.8%-$584K-8.8%-$572K-9.4%
$5.12M-74.3%$74.58M+390%$47.58M+381%$19.95M-55.6%
$0$2K-87.5%$2K-96.6%$31K-54.4%
$0-$2K+87.5%-$2K+96.6%-$31K+54.4%
$122K-39.9%$0$88K-88.3%$6K-99.9%
$122K+101%$0+100%$88K+100%$6K+100%
-$106K-1,414%-$26K0.0%-$647K-1,169%-$7K-129%
$5.02M-74.8%$75.05M$47.56M+375%$19.92M-32.2%
$7.58M-6.8%$7.58M-6.8%$7.58M-6.8%$7.58M-6.8%
$885.75K-57.9%$885.75K-57.9%$885.75K-57.9%$885.75K-57.9%
$443K-7.5%$460K-5.2%$475K-6.3%$467K-7.7%$479K-6.6%
-$1.1M-4.6%-$274K+90.0%-$1.17M-$1.61M+68.8%-$1.05M+88.8%
-$621K-8.6%-$612K-8.9%-$603K-8.8%-$584K-8.8%-$572K-9.4%
-$219K-217%$0+100%$249K-94.4%$3.67M-36.5%$187K-84.0%
-$121K+14.2%-$100K-$63K-$143K-114%-$141K-370%
-$6M-1,573%-$1.09M+52.1%$248K$64K$407K-84.4%
$444K+8.6%$435K+8.2%$426K+8.4%$418K+8.6%$409K+8.2%
$419K+0.7%$418K+0.7%$418K+19.4%$416K-24.4%$416K-29.4%
$122K-39.9%$0$88K-88.3%$6K-99.9%
$885.75K-57.9%$885.75K-57.9%$885.75K-57.9%$885.75K-57.9%
$74.58M+390%$47.58M+382%$19.92M-55.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Ironwood Pharmaceuticals generate?
Ironwood Pharmaceuticals (IRWD) generated $147.2M in operating cash flow over the trailing twelve months.
Where does Ironwood Pharmaceuticals's cash flow data come from?
Every line is extracted from Ironwood Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.